FDA-approved GLP-1 receptor agonist containing 6mg/ml liraglutide. Clinical trials demonstrate 5-10% body weight reduction in 56 weeks when combined with lifestyle modifications. Designed for subcutaneous administration with ±2% dosing accuracy in obesity management protocols.

Packaging Specifications:
• 3ml pre-filled pen (6mg/ml concentration)
• Sterile single-patient use device
• Cold chain storage: 2°C–8°C (unopened)
• 30-day in-use stability at 15°C–30°C

*Prescription medication requiring medical supervision. Discontinue if hypersensitivity reactions occur. Dispose per biohazard protocols (Sharps Container). Clinical efficacy correlates with BMI ≥30 or ≥27 with comorbidities. Individual results may vary based on adherence to 12-week lifestyle intervention program.